Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
about
Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactamsExtended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unitRandomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients.2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.Evaluation of imipenem 1.5 g daily in febrile patients with short duration neutropenia after chemotherapy for non-leukemic hematologic malignancies and solid tumors: personal experience and review of the literature.The Dose-Dependent Efficacy of Cefepime in the Empiric Management of Febrile Neutropenia: A Systematic Review and Meta-Analysis.Cefepime monotherapy for treatment of febrile neutropenia in children.Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.Bacteremia in patients with hematological malignancies.Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost.Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer.A randomized open label study of 'imipenem vs. cefepime' in spontaneous bacterial peritonitis.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.
P2860
Q24236653-7C1A0A45-C452-4B7C-BB11-BCF3C7136D48Q28950856-335D2219-D59B-4BF4-A79F-029963D7AB98Q31918096-B5C5AEC7-4E32-4876-A96D-CE07A0ADF7C3Q34114674-12DE71B6-CD52-4796-8F56-179EB4D201BCQ35137177-689EF5C9-37BF-432F-AC34-35159C8F2809Q40111888-9E923E32-53E0-4D93-A2F0-052A2567D5A0Q40465101-AD26FB9E-E1B5-4B95-B99C-D241F1497DEFQ40484723-4EE3C4A9-CAB3-41D7-87CB-D30F2EC7B1F6Q40508848-5E6581C5-6B5F-4104-8167-48598208D14BQ40512932-646CDDEF-B8D2-4238-BE77-FAF2B2C7B660Q40615385-343A6621-14B1-4D04-844F-BE70CA94986DQ41209156-0F2C9248-C0E9-43B4-BE35-AE8DDA5E5C30Q51617424-4E204A2F-6380-461D-BCC9-CE8A10007737
P2860
Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Cefepime versus imipenem-cilas ...... nfectious Diseases in Cancer).
@en
Cefepime versus imipenem-cilas ...... rt duration neutropenia. CEMIC
@nl
type
label
Cefepime versus imipenem-cilas ...... nfectious Diseases in Cancer).
@en
Cefepime versus imipenem-cilas ...... rt duration neutropenia. CEMIC
@nl
prefLabel
Cefepime versus imipenem-cilas ...... nfectious Diseases in Cancer).
@en
Cefepime versus imipenem-cilas ...... rt duration neutropenia. CEMIC
@nl
P2093
P356
P1476
Cefepime versus imipenem-cilas ...... nfectious Diseases in Cancer).
@en
P2093
Fuhrmann C
Lefebvre D
Soler-Michel P
P304
P356
10.1093/JAC/42.4.511
P407
P577
1998-10-01T00:00:00Z